# OnCo record early-stage-classical-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "early-stage-classical-hodgkin-lymphoma" ;
  schema:name "Early-stage classical Hodgkin lymphoma (stage I to II)"@en ;
  schema:alternateName "Limited-stage Hodgkin lymphoma"@en, "Stage I to II classical Hodgkin lymphoma"@en, "Early favourable and early unfavourable Hodgkin lymphoma"@en, "Localised Hodgkin lymphoma"@en ;
  schema:description "Early-stage classical Hodgkin lymphoma is Hodgkin lymphoma confined to one or two lymph node regions on one side of the diaphragm, one of the most curable cancers, with most patients cured by a short course of ABVD chemotherapy with or without radiotherapy to the involved nodes. Because patients are young, trials now use PET scans after two cycles to give as little treatment as safely possible."@en ;
  schema:url <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1000067>, <https://doi.org/10.1056/NEJMoa1408648>, <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/mammography/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/late-effects/> ;
  onco:trials <https://onco.cc/trials/ahod2131/>, <https://onco.cc/trials/nct03407144/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/>, <https://onco.cc/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/>, <https://onco.cc/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/> ;
  onco:pipeline <https://onco.cc/trials/ahod2131/>, <https://onco.cc/trials/nct03407144/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:standardOfCare <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/terms/late-effects/> .